Bulls REASONS TO BUY
Bears REASONS TO SELL
April 17, 2014
Company Update (NYSE:BMY): Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fi...
(Jutia Group, 4/14/14)
[Business Wire] - Bristol-Myers Squibb Company...(read more)
Market Update (NYSE:BMY): Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US...
(Jutia Group, 4/7/14)
[Business Wire] - Bristol-Myers Squibb Company announced today that they have submitted new drug applications...(read more)
(Samurai Trader, 10/28/13)
BMY was one of few breakouts today, and is interesting in a couple of things I noticed here. First off, this is a cup and handle pattern, but the handle is rising rather than sloping down, which (if I recall correctly) is...(read more)
Bristol-Myers Squibb Company (BMY) Company Overview
This article is about Bristol-Myers Squibb. For the article on the company with ticker BMS, see Bemis Company (BMS).
Bristol-Myers Squibb (NYSE: BMY) is one of the world's largest pharmaceutical companies by total sales. Bristol-Myers Squibb offers treatments for cardiovascular disease, HIV/AIDS, hepatitis, cancer, and rheumatoid arthritis. Cancer treatments in particular represent a major portion of the company's long-term growth potential and have historically been a strong suit of Bristol-Myers Squibb. The company's top three blockbuster drugs (annual sales >$1 billion) are blood thinner Plavix, Abilify for schizophrenia, and Reyataz for HIV. In FY 2010, BMY generated revenues of $19.5B and net earnings of $3.1B.(Read more at Wikinvest )
What's in this BMY analysis on Wikinvest...